The India biosimilar market is witnessing rapid expansion due to the increasing burden of chronic diseases, growing demand for cost-effective biologics, and advancements in biotechnology. With a market size of INR 4.37 billion in 2024, the industry is expected to register a robust CAGR of 14.20% from 2025 to 2034, reaching INR 16.49 billion by 2034.
India has emerged as one of the most promising biosimilar-producing countries, thanks to its strong pharmaceutical manufacturing base, skilled workforce, and government initiatives supporting affordable biologics. The rising prevalence of diseases such as cancer, autoimmune disorders, and diabetes has accelerated the demand for biosimilars, as they offer effective therapeutic outcomes at lower costs compared to reference biologics.
Overview of the India Biosimilar Market
Biosimilars are biologic medical products that are highly similar to already approved biologic reference drugs, offering equivalent safety, efficacy, and quality. The biosimilar market in India has seen remarkable progress due to strong domestic demand, increasing R&D investments, and regulatory support from the Central Drugs Standard Control Organization (CDSCO).
The Indian pharmaceutical sector’s reputation as a global leader in generics has laid the foundation for its biosimilar success. Major Indian companies such as Biocon Limited, Dr. Reddy’s Laboratories, and Intas Pharmaceuticals are now competing on a global scale with leading multinationals like Pfizer, Amgen, and Novartis.
Additionally, India’s cost-effective manufacturing and clinical trial capabilities make it a preferred destination for biosimilar development and production.
India Biosimilar Market Size and Share
The India biosimilar market size reached INR 4.37 billion in 2024, with strong contributions from oncology, autoimmune disorders, and growth hormone deficiency treatments. The industry’s share in the global biosimilar landscape continues to rise, supported by rising domestic consumption and export growth.
Forecast Period (2025–2034): CAGR of 14.20%
Projected Market Value by 2034: INR 16.49 billion
Key Market Share Insights:
Monoclonal antibodies hold a significant share due to their use in oncology and autoimmune diseases.
Recombinant hormones are gaining traction for treating hormonal deficiencies and metabolic disorders.
The contract manufacturing segment is growing rapidly as multinational companies partner with Indian manufacturers for cost-efficient production.
Request sample report: https://www.expertmarketresearch.com/reports/india-biosimilar-market/requestsample
Market Dynamics and Emerging Trends
Drivers
Rising prevalence of chronic diseases: Increasing cases of cancer, diabetes, and autoimmune disorders are fueling biosimilar adoption.
Affordable healthcare demand: Biosimilars offer up to 30–50% lower costs than originator biologics, making them more accessible.
Government support: Regulatory simplifications and initiatives like “Make in India” and “Ayushman Bharat” encourage domestic biosimilar manufacturing.
Biopharmaceutical innovation: Indian biotech firms are investing heavily in advanced technologies like recombinant DNA and cell line development.
Trends
Expansion of oncology biosimilars: A growing number of biosimilars are being approved for oncology applications, targeting blockbuster biologics.
Partnerships and collaborations: Companies are forming strategic alliances for co-development and commercialization.
Increased R&D focus: Investment in clinical trials and molecular characterization is enhancing biosimilar credibility.
Export opportunities: Indian biosimilars are expanding globally, particularly in emerging economies with cost-sensitive healthcare systems.
Market Growth Outlook
The India biosimilar market growth is driven by a combination of scientific advancement, regulatory reforms, and increased healthcare spending. As the Indian population ages and chronic conditions rise, biosimilars will play a critical role in ensuring access to affordable biologics.
With a projected value of INR 16.49 billion by 2034, the sector will contribute significantly to India’s position as a global biopharmaceutical hub. Moreover, international regulatory harmonization, including U.S. FDA and EMA approvals for Indian biosimilars, is likely to further strengthen exports.
Market Opportunities and Challenges
Opportunities
Untapped therapeutic areas: Expansion into new segments such as cardiovascular and neurological disorders.
Collaborative R&D: Partnerships between Indian and global pharmaceutical firms for advanced biosimilar development.
Export expansion: Growing international acceptance of Indian biosimilars in Latin America, Africa, and Asia-Pacific.
Regulatory advancements: Evolving guidelines are supporting faster and smoother product approvals.
Challenges
High R&D investment costs: Biosimilar development requires significant investment in clinical trials and analytical testing.
Complex manufacturing processes: Maintaining product similarity and stability remains a technological challenge.
Market competition: Increasing competition among local and global players may lead to pricing pressures.
Regulatory hurdles: Compliance with international biosimilar standards can delay market entry.
Market Breakup by Product Class
Monoclonal Antibodies: Widely used in oncology and autoimmune treatments, leading the market segment.
Recombinant Hormones: Crucial in treating hormonal disorders and metabolic conditions.
Immunomodulators: Used for immune system regulation and chronic disease management.
Anti-Inflammatory Agents: Gaining popularity for conditions like arthritis and inflammatory bowel disease.
Other Product Classes: Include biosimilars for rare diseases and specialty treatments.
Market Breakup by Manufacturing Type
In-House Manufacturing: Adopted by companies with advanced facilities and strong R&D infrastructure like Biocon and Dr. Reddy’s.
Contract Manufacturing: Growing rapidly as smaller companies outsource production to reduce operational costs and speed up market entry.
Market Breakup by Applications
Oncology: Largest segment due to rising cancer prevalence and increasing acceptance of biosimilar monoclonal antibodies.
Chronic and Autoimmune Disorders: Significant demand driven by conditions like rheumatoid arthritis and psoriasis.
Blood Disorders: Includes biosimilars for hemophilia and anemia.
Growth Hormonal Deficiency: Rising pediatric and adult patient base supports demand.
Other Applications: Encompass metabolic and cardiovascular disorders.
Recent Developments in the India Biosimilar Market
Biocon Biologics expanded its biosimilar portfolio with approvals for insulin glargine and bevacizumab in key global markets.
Dr. Reddy’s Laboratories launched pegfilgrastim and trastuzumab biosimilars, enhancing its oncology pipeline.
Intas Pharmaceuticals partnered with European firms for biosimilar distribution in emerging markets.
Pfizer and Samsung Bioepis expanded their global biosimilar collaborations, increasing their focus on India.
Government initiatives promoting biotech innovation and indigenous manufacturing continue to strengthen domestic capabilities.
Competitor Analysis
The India biosimilar market is highly competitive, featuring both domestic leaders and international giants. Companies are focusing on product diversification, partnerships, and global market expansion.
Key Players Include:
Biocon Limited – India’s leading biosimilar producer with a strong global footprint.
Dr. Reddy’s Laboratories – Active in oncology and autoimmune biosimilars with multiple global approvals.
Intas Pharmaceutical Ltd. – Specializing in monoclonal antibody development.
Pfizer Inc. – Global leader expanding its biosimilar pipeline in India.
Novartis AG – Through Sandoz, offers a wide biosimilar portfolio.
Amgen Inc. – Focuses on innovative biologic therapies and biosimilar launches.
Celltrion Healthcare, Eli Lilly, Viatris Inc., Samsung Bioepis, Stada Arzneimittel AG, Teva Pharmaceutical Industries, LG Life Sciences, Coherus Biosciences, and Biocad – All contribute to the evolving competitive ecosystem.
Future Outlook
The India biosimilar market is set for sustained growth over the next decade, propelled by supportive policies, growing healthcare access, and rising acceptance of biosimilars among physicians and patients. Increasing investments in biotechnology parks, R&D collaborations, and regulatory harmonization will further boost market performance.
With the global shift toward biologics and biosimilars, India is well-positioned to become a global biosimilar innovation and manufacturing hub, offering affordable therapies worldwide.
FAQs
1. What is the current size of the India biosimilar market?
The India biosimilar market was valued at INR 4.37 billion in 2024 and is expected to grow at a CAGR of 14.20%, reaching INR 16.49 billion by 2034.
2. What factors are driving the growth of the India biosimilar market?
Key drivers include the rising prevalence of chronic diseases, affordability of biosimilars, technological advancements, and government initiatives supporting domestic manufacturing.
3. Which product class dominates the biosimilar market in India?
Monoclonal antibodies dominate the market due to their widespread use in oncology and autoimmune disease treatments.
4. Who are the leading players in the India biosimilar market?
Top companies include Biocon Limited, Dr. Reddy’s Laboratories, Intas Pharmaceuticals, Pfizer, and Amgen.
5. What are the main challenges faced by the Indian biosimilar industry?
Challenges include high R&D costs, complex manufacturing requirements, regulatory compliance, and intense market competition.
